Reversal of proteinuric renal disease and the emerging role of endothelin

Nature Clinical Practice Nephrology

Volumn 4, Issue 9, 2008, Pages 490-501

  Barton, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Endothelin; Glomerulosclerosis; Podocyte; Proteinuria; Reversal

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; AVOSENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERALOCORTICOID RECEPTOR;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CELL DAMAGE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG TARGETING; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY PARENCHYMA; MESANGIUM CELL; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; PROTEINURIC RENAL DISEASE; RENAL PROTECTION; REVIEW; RISK FACTOR; TREATMENT PLANNING;

DISEASE PROGRESSION; ENDOTHELIN-1; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; PROTEINURIA; RECEPTORS, ENDOTHELIN;

EID: 50249165289     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0891     Document Type: Review

References (128)

1. Remuzzi G et al. (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296
2. Jaber BL and Madias NE (2005) Progression of chronic kidney disease: can it be prevented or arrested? Am J Med 118: 1323-1330
3. de Borst MH et al. (2008) Primer: strategies for identifying genes involved in renal disease. Nat Clin Pract Nephrol 4: 265-276
4. Collins AJ et al. (2005) Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 45 (1 suppl 1): A5-A7, S1-S280
5. Xue JL et al. (2001) Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12: 2753-2758
6. Eijkelkamp WB et al. (2007) Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18: 1540-1546
7. Fogo AB (2001) Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804-819
8. Fogo AB (2005) New capillary growth: a contributor to regression of sclerosis? Curr Opin Nephrol Hypertens 14: 201-203
9. Fogo AB (2006) Progression versus regression of chronic kidney disease. Nephrol Dial Transplant 21: 281-284
10. Dussaule JC and Chatziantoniou C (2007) Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ 14: 1343-1349
11. Shankland SJ (2006) The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147
12. Reiser J et al. (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827-34832
13. Floege J et al. (1997) Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 51: 230-243
14. Opocensky M et al. (2006) Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48: 965-971
15. Nagase M et al. (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093
16. Shibata S et al. (2006) Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17: 754-764
17. Shibata S et al. (2007) Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49: 355-364
18. Asanuma K and Mundel P (2003) The role of podocytes in glomerular pathobiology. Clinical Exp Nephrol 7: 255-259
19. Ziyadeh FN and Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45
20. Kalluri R (2006) Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 17: 2383-2389
21. Mahan JD et al. (1986) Glomerular basement membrane anionic charge site changes early in aminonucleoside nephrosis. Am J Pathol 125: 393-401
22. Rastaldi MP et al. (2006) Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J 20: 976-978
23. Ortmann J et al. (2004) Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44: 974-981
24. Mundel P (2003) Urinary podocytes: lost and found alive. Kidney Int 64: 1529-1530
25. Petermann A and Floege J (2007) Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 106: c61-c66
26. Kim YH et al. (2001) Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60: 957-968
27. Macconi D et al. (2006) Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 168: 1073-1085
28. Gross ML et al. (2003) ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46: 856-868
29. Gagliardini E et al. (2007) Effect of a selective ETA receptor antagonist on podocyte function and permselective properties of the glomerular barrier in experimental diabetes. Presented at the 10th International Conference on Endothelin: 2007 Bergamo, September 16-19, Bergamo, Italy
30. Smoyer WE et al. (1997) Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am J Physiol 273: F150-F157
31. Shankland SJ et al. (2007) Podocytes in culture: past, present, and future. Kidney Int 72: 26-36
32. Yuan H et al. (2002) Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. Am J Physiology Renal Physiol 282: F585-F591
33. Gubler MC (2003) Podocyte differentiation and hereditary proteinuria/nephrotic syndromes. J Am Soc Nephrol 14 (suppl 1): S22-S26
34. Endlich N et al. (2001) Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12: 413-422
35. Takeda T et al. (2001) Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 108: 289-301
36. Benigni A et al. (2004) Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Semin Nephrol 24: 131-140
37. Furchgott RF and Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 299: 373-376
38. Yanagisawa M et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415
39. Barton M and Yanagisawa M: Endothelin - twenty years from discovery to therapy. Can J Physiol Pharmacol, in press
40. Rubanyi GM and Polokoff M (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46: 325-415
41. Ge Y et al. (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280
42. Luscher TF and Barton M (2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440
43. Kohan DE (2006) The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 15: 34-40
44. Benigni A et al. (1993) A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44: 440-444
45. Hocher B et al. (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389
46. Barton M et al. (2000) Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 11: 835-845
47. Vernerová Z et al. (2008) Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol 48: 165-173
48. Boffa JJ et al. (2001) Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490-496
49. Benigni A et al. (1998) Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47: 450-456
50. Gross ML et al. (2003) Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 83: 1267-1277
51. Benigni A and Remuzzi G (2001) How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 37: S21-S24
52. Gutierrez S et al. (1996) Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur J Pharmacol 302: 191-197
53. Chang JM et al. (2007) Effects of endothelin-1 on thymidine uptake and fibronectin production of diabetic glomeruli. Nephrology (Carlton) 12: 62-66
54. Morigi M et al. (2006) Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol 169: 1965-1975
55. Morigi M et al. (2005) In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166: 1309-1320
56. Nett PC et al. (2006) Recent developments on endothelin antagonists as immunomodulatory drugs-from infection to transplantation medicine. Recent Patents Cardiovasc Drug Discov 1: 265-276
57. Lattmann T et al. (2005) Activation of proinflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling. Am J Transplant 5: 1042-1049
58. Sasser JM et al. (2007) Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143-154
59. Xia HJ et al. (2006) Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci 79: 1812-1819
60. Gomez-Garre D et al. (1996) An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50: 962-972
61. Kawaguchi H et al. (1990) Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 22: 839-842
62. Barton M et al. (2000) Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 35: 329-336
63. Barton M et al. (1997) Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 238: 861-865
64. Rebibou JM et al. (1992) Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 7: 288-292
65. Jia J et al. (2008) Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 28: 500-507
66. Zoja C et al. (1999) Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7: 420-428
67. Wesson DE et al. (2007) Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 71: 210-217
68. Liang XB et al. (2006) Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 17: 1886-1895
69. Benigni A et al. (2004) The potential of endothelin antagonism as a therapeutic approach. Expert Opin Investig Drugs 13: 1419-1435
70. Gross ML and Amann K (2004) Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens 13: 307-312
71. Zanatta CM et al. (2008) Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 80: 299-304
72. Chen HC et al. (2001) Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis. J Clin Lab Anal 15: 59-63
73. Susztak K et al. (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233
74. Zhou X et al. (1995) High glucose alters actin assembly in glomerular mesangial and epithelial cells. Lab Invest 73: 372-383
75. Petermann AT et al. (2003) Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 64: 1222-1231
76. Collino F et al. (2008) Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 294: F1185-F1194
77. Chen HM et al. (2006) Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 48: 772-779
78. Saraheimo M et al. (2008) Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 31: 1165-1169
79. Sharma K et al. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 188: 1645-1656
80. Barton M et al. (2003) Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 35: 826-837
81. Bedi D et al. (2006) Endothelin-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5-bisphosphate/actin-dependent mechanism. Biochem Biophys Res Commun 345: 332-339
82. Juan CC et al. (2004) Insulin infusion induces endothelin-1-dependent hypertension in rats. Am J Physiol Endocrinol Metab 287: E948-E954
83. Yang Z and Li JC (2008) Stimulation of endothelin-1 gene expression by insulin via phosphoinositide-3 kinase-glycogen synthase kinase-3beta signaling in endothelial cells. Life Sci 82: 512-518
84. Idris I et al. (2001) Tissue- and time-dependent effects of endothelin-1 on insulin-stimulated glucose uptake. Biochem Pharmacol 62: 1705-1708
85. Aaltonen P et al. (2001) Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 81: 1185-1190
86. Ortmann J et al. (2005) Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. Biochem Biophys Res Commun 334: 689-695
87. Mauer SM et al. (1974) Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat. Diabetes 23: 748-753
88. Lee CS et al. (1974) Renal transplantation in diabetes mellitus in rats. J Exp Med 139: 793-800
89. Abouna GM et al. (1983) Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet 2: 1274-1276
90. Fioretto P et al. (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75
91. Marinides GN et al. (1990) Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 37: 749-757
92. Zoja C et al. (1992) Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. Am J Med 92: 60S-63S
93. Remuzzi A et al. (2006) ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 69: 1124-1130
94. Fujita T et al. (2007) Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72: 1543-1549
95. Ikoma M et al. (1991) Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40: 195-202
96. Ostendorf T et al. (1999) VEGF(165) mediates glomerular endothelial repair. J Clin Invest 104: 913-923
97. Ding SS et al. (2003) Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42: 48-54
98. Hocher B et al. (2001) Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87: 161-169
99. Kelly DJ et al. (2000) Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 57: 1882-1894
100. Schiffrin EL (1999) State-of-the-Art lecture. Role of endothelin-1 in hypertension. Hypertension 34: 876-881
101. Placier S et al. (2006) Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant 21: 881-888
102. Barton M et al. (1998) ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31: 499-504
103. Honing MLH et al. (2000) ABT-627, a selective ETA-receptor anatagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-derived Mediators [thesis] Utrecht: Elinkwijk BV
104. Wenzel RR et al. (2005) The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy [abstract F-FC093]. Presented at ASN Renal Week: 2005 November 8-13, Philadelphia, PA, USA
105. Mann J et al. (2006) Avosentan, a selective endothelin receptor antagonist, decreases albuminuria in patients with diabetic nephropathy. [http://www.associationhq.com/isn/forefronts/pages/abstractview.php?id= 2&page=0] (accessed 5 June 2008)
106. Viberti G (online 2008) SPP301 (Avosentan) ASCEND clinical results. [www.speedel.com/assets/2008_SPP301ASCENDStudy.pdf] (accessed 5 June 2008)
107. ClinicalTrials.gov (online 2005) [http://clinicaltrials.gov/ct2/show/ NCT00120328?term=NCT00120328&rank=1] (accessed 5 June 2008)
108. Barton M et al. (2006) Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials. Hypertension 48: 834-837
109. Black HR et al. (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9: 760-769
110. Hernandez-Perera O et al. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719
111. Whaley-Connell A et al. (2008) Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 51: 474-480
112. Eyre J et al. (2007) Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol 292: F674-F681
113. Danesh FR et al. (2002) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 99: 8301-8305
114. Whaley-Connell A et al. (2008) Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 28: 67-75
115. Gianella A et al. (2007) Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 170: 1165-1177
116. Aldigier JC et al. (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314
117. Zeng ZP et al. (1992) Endothelin stimulates aldosterone secretion in vitro from normal adrenocortical tissue, but not adenoma tissue, in primary aldosteronism. J Clin Endocrinol Metab 74: 874-878
118. Rossi GP et al. (1997) Autocrine-paracrine role of endothelin-1 in the regulation of aldosterone synthase expression and intracellular Ca2+ in human adrenocortical carcinoma NCI-H295 cells. Endocrinology 138: 4421-4426
119. Wang S et al. (2003) Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63: 2037-2049
120. Zeisberg M et al. (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968
121. Kitten AM et al. (1997) Osteogenic protein-1 downregulates endothelin A receptors in primary rat osteoblasts. Am J Physiol 272: E967-E975
122. De Petris L et al. (2007) Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 22: 3442-3450
123. Mitu GM et al. (2007) BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am Journal Physiol 293: F1641-F1648
124. Ueda H et al. (2008) BMP in podocytes is essential for normal glomerular capillary formation. J Am Soc Nephrol 19: 685-694
125. Parving HH et al. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446
126. Benigni A and Remuzzi G (1998) Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking? Nephrol Dial Transplant 13: 2734-2738
127. Harman C (2007) What new drugs can nephrologists look forward to in the next year or two? Nat Clin Pract Nephrol 3: 235
128. Orisio S et al. (2007) The SNP5333 gene polymorphism of endothelin A receptor is independently associated with increased albuminuria in type 2 diabetes. Presented at the 10th International Conference on Endothelin: 2007 Bergamo, September 16-19, Bergamo, Italy